Skip to content
OpenCapital
Get started

CEPT CEPT Forward Sale Securities Liability Non Current

Forward Sale Securities Liability Non Current at other companies

Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
$309M—
Aspen Aerogels logo
Aspen AerogelsASPN
$3.22M-61.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.02B+9.3%
Mannkind logo
MannkindMNKD
$136.56M-0.6%
Mannkind logo
MannkindMNKD
$14.01M+9.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+42.1%

Other financials

Income statement

See full
Operating income-$1.5M-5,352%
Net income$2.4M+8,927%
EPS (diluted)$0.00—

Balance sheet

See full
Cash & equivalents$25.0K—
Total equity-$9.5M-9,877%
Total assets$249.0M+153,869%

Cash flow

See full
Operating cash flow$56.6K+705%

Valuation

See full
Market cap$310.39M-7.5%
P/E50.3×—

Returns & leverage

See full
Return on equity-128.8%—
Current ratio0.1×—

Where this comes from

Reported directly by CEPT in its filing.

Tagged under the XBRL concept cept:ForwardSaleSecuritiesLiabilityNonCurrent.

The official record: CEPT’s 10-K, filed March 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about CEPT's forward sale securities liability non current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CEPT's forward sale securities liability non current?
CEPT (CEPT) reported forward sale securities liability non current of $4.61M in Q4 2025.
What does forward sale securities liability non current mean?
This represents the long-term financial obligation arising from forward sale agreements of securities, where the company is committed to delivering shares or assets at a future date. It reflects the company's long-term capital structure commitments and potential dilution risks. Monitoring this helps investors understand future equity issuance obligations and balance sheet leverage.